L3VLUP
ProSign in
← Farallon Capital Management LLC, latest filing

What Farallon Capital Management LLC changed, 2013 to 2026

53 quarterly 13F filings, from Q2 2013 to Q2 2026, each read from the filing itself. A quarter is compared only with the quarter before it, so a quarter with no filing is a gap in the record, not a sale.

Reported book

$21.7bn

$5.2bn at Q2 2013

Positions

89

82 at Q2 2013

Top ten weight

62%

42% at Q2 2013

Typical quarterly turnover

about 21%

Estimated from share changes

Reported book by quarter
$0$12bn$24bnQ2 2013: $5.2bnQ3 2013: $4.9bnQ4 2013: $4.8bnQ1 2014: $5.1bn14Q2 2014: $6.9bnQ3 2014: $6.2bnQ4 2014: $7.3bnQ1 2015: $6.8bn15Q2 2015: $7.4bnQ3 2015: $7.6bnQ4 2015: $11.2bnQ1 2016: $10.5bn16Q2 2016: $7.3bnQ3 2016: $6.8bnQ4 2016: $8.7bnQ1 2017: $9.1bn17Q2 2017: $9.6bnQ3 2017: $11.3bnQ4 2017: $12.3bnQ1 2018: $14.4bn18Q2 2018: $16.2bnQ3 2018: $16.9bnQ4 2018: $13.6bnQ1 2019: $13.3bn19Q2 2019: $15.4bnQ3 2019: $13.2bnQ4 2019: $14.8bnQ1 2020: $11.7bn20Q2 2020: $12.5bnQ3 2020: $14.5bnQ4 2020: $16.6bnQ1 2021: $20.1bn21Q2 2021: $24.5bnQ3 2021: $21.4bnQ4 2021: $20.0bnQ1 2022: $20.7bn22Q2 2022: $18.4bnQ3 2022: $18.2bnQ4 2022: $16.9bnQ1 2023: $18.3bn23Q2 2023: $19.9bnQ3 2023: $21.4bnQ4 2023: $21.9bnQ1 2024: $23.6bn24Q2 2024: $23.3bnQ3 2024: $22.8bnQ4 2024: $22.8bnQ1 2025: $20.9bn25Q2 2025: $23.8bnQ3 2025: $24.4bnQ4 2025: $23.1bnQ1 2026: $19.1bn26Q2 2026: $21.7bn
  • Q2 2013: $5.2bn
  • Q3 2013: $4.9bn
  • Q4 2013: $4.8bn
  • Q1 2014: $5.1bn
  • Q2 2014: $6.9bn
  • Q3 2014: $6.2bn
  • Q4 2014: $7.3bn
  • Q1 2015: $6.8bn
  • Q2 2015: $7.4bn
  • Q3 2015: $7.6bn
  • Q4 2015: $11.2bn
  • Q1 2016: $10.5bn
  • Q2 2016: $7.3bn
  • Q3 2016: $6.8bn
  • Q4 2016: $8.7bn
  • Q1 2017: $9.1bn
  • Q2 2017: $9.6bn
  • Q3 2017: $11.3bn
  • Q4 2017: $12.3bn
  • Q1 2018: $14.4bn
  • Q2 2018: $16.2bn
  • Q3 2018: $16.9bn
  • Q4 2018: $13.6bn
  • Q1 2019: $13.3bn
  • Q2 2019: $15.4bn
  • Q3 2019: $13.2bn
  • Q4 2019: $14.8bn
  • Q1 2020: $11.7bn
  • Q2 2020: $12.5bn
  • Q3 2020: $14.5bn
  • Q4 2020: $16.6bn
  • Q1 2021: $20.1bn
  • Q2 2021: $24.5bn
  • Q3 2021: $21.4bn
  • Q4 2021: $20.0bn
  • Q1 2022: $20.7bn
  • Q2 2022: $18.4bn
  • Q3 2022: $18.2bn
  • Q4 2022: $16.9bn
  • Q1 2023: $18.3bn
  • Q2 2023: $19.9bn
  • Q3 2023: $21.4bn
  • Q4 2023: $21.9bn
  • Q1 2024: $23.6bn
  • Q2 2024: $23.3bn
  • Q3 2024: $22.8bn
  • Q4 2024: $22.8bn
  • Q1 2025: $20.9bn
  • Q2 2025: $23.8bn
  • Q3 2025: $24.4bn
  • Q4 2025: $23.1bn
  • Q1 2026: $19.1bn
  • Q2 2026: $21.7bn
Share of the book in the ten largest positions
0%31%62%Q2 2013: 42%Q3 2013: 42%Q4 2013: 39%Q1 2014: 41%14Q2 2014: 40%Q3 2014: 37%Q4 2014: 41%Q1 2015: 41%15Q2 2015: 48%Q3 2015: 47%Q4 2015: 58%Q1 2016: 60%16Q2 2016: 56%Q3 2016: 54%Q4 2016: 52%Q1 2017: 49%17Q2 2017: 53%Q3 2017: 57%Q4 2017: 58%Q1 2018: 54%18Q2 2018: 54%Q3 2018: 56%Q4 2018: 51%Q1 2019: 48%19Q2 2019: 55%Q3 2019: 51%Q4 2019: 44%Q1 2020: 46%20Q2 2020: 33%Q3 2020: 32%Q4 2020: 31%Q1 2021: 33%21Q2 2021: 39%Q3 2021: 34%Q4 2021: 37%Q1 2022: 38%22Q2 2022: 32%Q3 2022: 32%Q4 2022: 35%Q1 2023: 38%23Q2 2023: 44%Q3 2023: 50%Q4 2023: 52%Q1 2024: 52%24Q2 2024: 48%Q3 2024: 40%Q4 2024: 40%Q1 2025: 40%25Q2 2025: 45%Q3 2025: 48%Q4 2025: 44%Q1 2026: 50%26Q2 2026: 62%
  • Q2 2013: 42%
  • Q3 2013: 42%
  • Q4 2013: 39%
  • Q1 2014: 41%
  • Q2 2014: 40%
  • Q3 2014: 37%
  • Q4 2014: 41%
  • Q1 2015: 41%
  • Q2 2015: 48%
  • Q3 2015: 47%
  • Q4 2015: 58%
  • Q1 2016: 60%
  • Q2 2016: 56%
  • Q3 2016: 54%
  • Q4 2016: 52%
  • Q1 2017: 49%
  • Q2 2017: 53%
  • Q3 2017: 57%
  • Q4 2017: 58%
  • Q1 2018: 54%
  • Q2 2018: 54%
  • Q3 2018: 56%
  • Q4 2018: 51%
  • Q1 2019: 48%
  • Q2 2019: 55%
  • Q3 2019: 51%
  • Q4 2019: 44%
  • Q1 2020: 46%
  • Q2 2020: 33%
  • Q3 2020: 32%
  • Q4 2020: 31%
  • Q1 2021: 33%
  • Q2 2021: 39%
  • Q3 2021: 34%
  • Q4 2021: 37%
  • Q1 2022: 38%
  • Q2 2022: 32%
  • Q3 2022: 32%
  • Q4 2022: 35%
  • Q1 2023: 38%
  • Q2 2023: 44%
  • Q3 2023: 50%
  • Q4 2023: 52%
  • Q1 2024: 52%
  • Q2 2024: 48%
  • Q3 2024: 40%
  • Q4 2024: 40%
  • Q1 2025: 40%
  • Q2 2025: 45%
  • Q3 2025: 48%
  • Q4 2025: 44%
  • Q1 2026: 50%
  • Q2 2026: 62%

The positions that defined it

Every position that was ever among the 25 largest: when it first appeared, when it was largest, and where it stands in Q2 2026. The line is its reported value each quarter.

PositionValue over timeFirst listedLargestQ2 2026
Spdr S&P 500 Etf Trust(SPY)Q3 2015$6.0bnQ1 2024$4.5bn
Revolution Medicines Inc(RVMD)Q1 2020$2.5bnQ2 2026$2.5bn
Electronic Arts Inc(EA)Q4 2025$1.6bnQ2 2026$1.6bn
Bridgebio Pharma Inc(BBIO)Q4 2023$800mQ2 2026$800m
Protagonist Therapeutics Inc(PTGX)Q4 2017$778mQ2 2026$778m
Exelixis Inc(EXEL)Q2 2016$832mQ1 2025$733m
Liquidia Technologies Inc(LQDA)Q1 2024$667mQ2 2026$667m
Amazon Com Inc(AMZN)Q2 2025$1.0bnQ4 2025$628m
Lantheus HLDGS Inc(LNTH)Q2 2020$619mQ2 2026$619m
Natera Inc(NTRA)Q2 2021$897mQ4 2025$602m
Unitedhealth Group Inc(UNH)Q1 2023$842mQ1 2024$528m
Thermo Fisher Scientific Inc(TMO)Q4 2019$723mQ1 2022$526m
Spdr S&P 500 Etf Trust(SPY)Q4 2024$3.4bnQ2 2025Soldlast listed Q2 2025
iShares IBOXX High Yield ETF(HYG)Q2 2025$3.2bnQ3 2025Soldlast listed Q4 2025
Altaba IncQ2 2017$2.0bnQ1 2019Soldlast listed Q3 2019
Activision Blizzard IncQ1 2022$1.9bnQ3 2023Soldlast listed Q3 2023
Spdr S&P 500 Etf Trust(SPY)Q3 2015$1.9bnQ4 2018Soldlast listed Q4 2021
Allergan PLCQ2 2015$1.6bnQ1 2020Soldlast listed Q1 2020
Celgene CorpQ1 2019$1.5bnQ3 2019Soldlast listed Q3 2019
Aetna Inc NewQ2 2015$1.5bnQ3 2018Soldlast listed Q3 2018

Quarter by quarter

2026Q1Q2
2025Q1Q2Q3Q4
2024Q1Q2Q3Q4
2023Q1Q2Q3Q4
2022Q1Q2Q3Q4
2021Q1Q2Q3Q4
2020Q1Q2Q3Q4
2019Q1Q2Q3Q4
2018Q1Q2Q3Q4
2017Q1Q2Q3Q4
2016Q1Q2Q3Q4
2015Q1Q2Q3Q4
2014Q1Q2Q3Q4
2013Q2Q3Q4

Q1 2020: $11.7bn across 102 positions

Against Q4 2019: 21 new, 39 added to, 23 trimmed, 33 sold out, across all 102 positions.

Turnover about 19% of the book, estimated from share changes at quarter-end prices.

Largest additions

  • Allergan PLC+$120m
  • Iqvia HLDGS Inc (IQV)+$117m
  • General Dynamics Corp (GD)+$103m
  • Acceleron Pharma Inc+$89m
  • Ihs Markit LTD+$89m
  • Abbvie Inc (ABBV)+$83m
  • Fidelity Natl Information SV (FIS)+$77m
  • Thermo Fisher Scientific Inc (TMO)+$75m

Largest reductions

  • Spdr S&P 500 Etf Trust (SPY)-$690m
  • Iac Interactivecorp-$207m
  • Myokardia Inc-$129m
  • Palo Alto Networks Inc (PANW)-$95m
  • Cigna Corp New (CI)-$85m
  • Amarin Corp PLC-$74m
  • Equinix Inc (EQIX)-$67m
  • Microsoft Corp (MSFT)-$57m

Opened

  • Centene Corp Del (CNC)$431m

Sold out

  • Wellcare Health Plans Incwas $793m
  • VanEck Vectors ETF Trust (SMH)was $354m
  • Medicines Cowas $282m
  • Zayo Group HLDGS Incwas $236m
  • S&P Global Inc (SPGI)was $175m
  • Anixter Intl Incwas $85m
  • Audentes Therapeutics Incwas $71m
  • Global Blood Therapeutics Inwas $60m

Largest positions, Q1 2020

The largest 25 of 102 reported positions.

PositionValueWeightOn the quarter
Allergan PLC$1.6bn14.1%Added
Spdr S&P 500 Etf Trust (SPY)$722m6.2%Trimmed
Fidelity Natl Information SV (FIS)$562m4.8%Added
Centene Corp Del (CNC)$431m3.7%New
Iqvia HLDGS Inc (IQV)$403m3.5%Added
Thermo Fisher Scientific Inc (TMO)$353m3.0%Added
Alphabet Inc (GOOG)$343m2.9%Added
Charter Communications Inc N (CHTR)$316m2.7%Added
Iac Interactivecorp$307m2.6%Trimmed
Abbvie Inc (ABBV)$305m2.6%Added
Wabtec Corp (WAB)$304m2.6%Added
Ihs Markit LTD$296m2.5%Added
Microsoft Corp (MSFT)$288m2.5%Trimmed
Visa Inc (V)$284m2.4%Added
Anthem Inc (ELV)$284m2.4%Held
General Dynamics Corp (GD)$276m2.4%Added
Sherwin Williams Co (SHW)$234m2.0%Added
Salesforce Com Inc (CRM)$232m2.0%Trimmed
Cigna Corp New (CI)$221m1.9%Trimmed
Alibaba Group HLDG LTD (BABA)$218m1.9%Trimmed
Acceleron Pharma Inc$195m1.7%Added
Facebook Inc (META)$181m1.6%Added
Equinix Inc (EQIX)$176m1.5%Trimmed
Exelixis Inc (EXEL)$172m1.5%Added
Iovance Biotherapeutics Inc (IOVA)$172m1.5%Trimmed

The books most like this one

Among the managers whose filings are on file, at Q2 2026. Overlap is the share of the two books that is the same: for every stock both list, the smaller of its two weights, added up. Two books can overlap because both own the largest companies; it says nothing about whether the managers agree.

ManagerOverlapStocks in bothOverlap over time
Janus Henderson Group Ltdat least 11%30Compare
Maverick Capital Ltd11%9Compare
Viking Global Investors LP11%8Compare
Woodline Partners LPat least 10%29Compare
MFS Investment Managementat least 10%18Compare
T. Rowe Price Associates Incat least 9.8%25Compare
Arrowstreet Capital LPat least 9.3%20Compare
Dodge & Cox9.3%18Compare

“At least” where either manager has more positions than are read each quarter: a stock both hold below that range is not counted.

The filings behind it

Every quarter above is one 13F holdings report, with any amendment the filer made to it applied in the order it was filed. Where the reporting entity changed, each quarter keeps the filer that actually reported it.

QuarterFilerBookAmendedFiling
Q2 2026Farallon Capital Management LLC$21.7bn13F-HR
Q1 2026Farallon Capital Management LLC$19.1bn113F-HR
Q4 2025Farallon Capital Management LLC$23.1bn213F-HR
Q3 2025Farallon Capital Management LLC$24.4bn13F-HR
Q2 2025Farallon Capital Management LLC$23.8bn213F-HR
Q1 2025Farallon Capital Management LLC$20.9bn313F-HR
Q4 2024Farallon Capital Management LLC$22.8bn413F-HR
Q3 2024Farallon Capital Management LLC$22.8bn413F-HR
Q2 2024Farallon Capital Management LLC$23.3bn513F-HR
Q1 2024Farallon Capital Management LLC$23.6bn413F-HR
Q4 2023Farallon Capital Management LLC$21.9bn313F-HR
Q3 2023Farallon Capital Management LLC$21.4bn413F-HR
Q2 2023Farallon Capital Management LLC$19.9bn313F-HR
Q1 2023Farallon Capital Management LLC$18.3bn313F-HR
Q4 2022Farallon Capital Management LLC$16.9bn313F-HR
Q3 2022Farallon Capital Management LLC$18.2bn413F-HR
Q2 2022Farallon Capital Management LLC$18.4bn513F-HR
Q1 2022Farallon Capital Management LLC$20.7bn513F-HR
Q4 2021Farallon Capital Management LLC$20.0bn513F-HR
Q3 2021Farallon Capital Management LLC$21.4bn513F-HR
Q2 2021Farallon Capital Management LLC$24.5bn613F-HR
Q1 2021Farallon Capital Management LLC$20.1bn613F-HR
Q4 2020Farallon Capital Management LLC$16.6bn413F-HR
Q3 2020Farallon Capital Management LLC$14.5bn213F-HR
Q2 2020Farallon Capital Management LLC$12.5bn213F-HR
Q1 2020Farallon Capital Management LLC$11.7bn213F-HR
Q4 2019Farallon Capital Management LLC$14.8bn113F-HR
Q3 2019Farallon Capital Management LLC$13.2bn213F-HR
Q2 2019Farallon Capital Management LLC$15.4bn413F-HR
Q1 2019Farallon Capital Management LLC$13.3bn313F-HR
Q4 2018Farallon Capital Management LLC$13.6bn213F-HR
Q3 2018Farallon Capital Management LLC$16.9bn13F-HR
Q2 2018Farallon Capital Management LLC$16.2bn13F-HR
Q1 2018Farallon Capital Management LLC$14.4bn13F-HR
Q4 2017Farallon Capital Management LLC$12.3bn13F-HR
Q3 2017Farallon Capital Management LLC$11.3bn13F-HR
Q2 2017Farallon Capital Management LLC$9.6bn13F-HR
Q1 2017Farallon Capital Management LLC$9.1bn13F-HR
Q4 2016Farallon Capital Management LLC$8.7bn13F-HR
Q3 2016Farallon Capital Management LLC$6.8bn13F-HR
Q2 2016Farallon Capital Management LLC$7.3bn13F-HR
Q1 2016Farallon Capital Management LLC$10.5bn13F-HR
Q4 2015Farallon Capital Management LLC$11.2bn13F-HR
Q3 2015Farallon Capital Management LLC$7.6bn13F-HR
Q2 2015Farallon Capital Management LLC$7.4bn13F-HR
Q1 2015Farallon Capital Management LLC$6.8bn13F-HR
Q4 2014Farallon Capital Management LLC$7.3bn13F-HR
Q3 2014Farallon Capital Management LLC$6.2bn13F-HR
Q2 2014Farallon Capital Management LLC$6.9bn13F-HR
Q1 2014Farallon Capital Management LLC$5.1bn13F-HR
Q4 2013Farallon Capital Management LLC$4.8bn13F-HR
Q3 2013Farallon Capital Management LLC$4.9bn13F-HR
Q2 2013Farallon Capital Management LLC$5.2bn13F-HR

Reading this record

A 13F lists US-listed long equity and options at the quarter end, filed up to 45 days later. It shows what was held, not when it was bought or at what price, and nothing short. Where a quarter lists only the largest positions, a name missing from it may still be held below that range; the counts of what was opened and sold always cover the whole filing.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More